These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 27864686)

  • 21. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis.
    Huang S; Lin H; Zhu X; Chen X; Fan L; Liu C
    Endokrynol Pol; 2014; 65(2):96-104. PubMed ID: 24802732
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy of zoledronic acid for osteoporosis:evidence from studies abroad.].
    Inoue D
    Clin Calcium; 2017; 27(2):247-255. PubMed ID: 28123127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data.
    Bell KJ; Hayen A; Glasziou P; Irwig L; Eastell R; Harrison SL; Black DM; Bauer DC
    J Bone Miner Res; 2016 Sep; 31(9):1767-73. PubMed ID: 27027655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia.
    Perifanis V; Vyzantiadis T; Tziomalos K; Vakalopoulou S; Garipidou V; Athanassiou-Metaxa M; Harsoulis F
    Ann Hematol; 2007 Jan; 86(1):23-30. PubMed ID: 17013645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of zoledronic acid in the management of osteoporosis.
    Maricic M
    Clin Rheumatol; 2010 Oct; 29(10):1079-84. PubMed ID: 20544246
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and Safety of Zoledronic Acid in the Treatment of Osteoporosis.
    Hsieh PC
    Orthopedics; 2016; 39(2):e263-70. PubMed ID: 26881461
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Zoledronic acid for prevention and treatment of osteoporosis.
    Recknor C
    Expert Opin Pharmacother; 2011 Apr; 12(5):807-15. PubMed ID: 21385149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 30. Zoledronic acid in osteoporosis secondary to mastocytosis.
    Rossini M; Zanotti R; Viapiana O; Tripi G; Idolazzi L; Biondan M; Orsolini G; Bonadonna P; Adami S; Gatti D
    Am J Med; 2014 Nov; 127(11):1127.e1-1127.e4. PubMed ID: 24954632
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous zoledronic acid for the treatment of osteoporosis.
    Lewiecki EM
    Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
    Bilbao J; Pugh A; Aspy CB
    J Okla State Med Assoc; 2010 Aug; 103(8):374-5. PubMed ID: 21049709
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF
    J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic effect of zoledronic acid on primary osteoporosis in elderly patients].
    Xu L; Deng H; Zhi X; Zhang W; Wang X; Wu W
    Nan Fang Yi Ke Da Xue Xue Bao; 2012 Sep; 32(9):1287-9. PubMed ID: 22985565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Medication-related osteonecrosis of the jaws from once per year intravenous zoledronic acid (Reclast): report of 4 cases.
    Lee CY; Suzuki JB
    Implant Dent; 2015 Apr; 24(2):227-31. PubMed ID: 25734948
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON.
    Popp AW; Buffat H; Cavelti A; Windolf M; Perrelet R; Senn C; Lippuner K
    Maturitas; 2014 Mar; 77(3):287-93. PubMed ID: 24485216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single annual injectable treatment for postmenopausal osteoporosis.
    Chapurlat RD
    Expert Opin Drug Deliv; 2008 May; 5(5):583-91. PubMed ID: 18491983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Minodronate for the treatment of osteoporosis.
    Kubo T; Shimose S; Matsuo T; Fujimori J; Ochi M
    Drugs Today (Barc); 2010 Jan; 46(1):33-7. PubMed ID: 20200694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.